Research Article
Immune Toxicity with Checkpoint Inhibition for Metastatic Melanoma: Case Series and Clinical Management
Table 1
Patient characteristics and immune-related adverse events.
| | Characteristics | Compassionate pembrolizumab |
| | Median age (range), yr | 65 (37–90) | | Male sex, number (%) | 32 (78%) | | Primary type | | | Cutaneous | 31 (76%) | | Mucosal | 2 (5%) | | Occult | 7 (17%) | | Unknown | 1 (2%) | | ECOG performance status, number (%) | | | 0-1 | 33 (81%) | | >1 | 7 (17%) | | Unknown | 1 (2%) | | Lactate dehydrogenase, number (%) | | | ≤ULN (≤250 U/L) | 7 (17%) | | >ULN (>250 U/L) | 29 (71%) | | Unknown | 5 (12%) | | Metastasis stage, number (%) | | | In-transit disease | 1 (2%) | | M1a | 5 (12%) | | M1b | 4 (10%) | | M1c | 31 (76%) | | Number of organ sites of disease | | | ≤3 | 24 (58%) | | >3 | 15 (37%) | | Unknown | 2 (5%) | | BRAF V600 mutation, number (%) | 10 (24%) | | Prior lines of treatment, number (%) | | | 0 | 10 (24%) | | 1 | 20 (49%) | | 2-3 | 10 (24%) | | Unknown | 1 (2%) | | Preexisting autoimmune condition | 2 (5%) | | Ipilimumab pretreated, number (%) | 26 (63%) | | Ipilimumab-related irAE, number (%) | 13 (50%) |
| | Rates of irAE during anti-PD-1 therapy | Any grade | Grade 3 or 4 |
| | Any | 22 (54%) | 4 (15%) | | Skin | 10 (24%) | 1 (2%) | | Arthralgia/arthritis | 9 (22%) | 1 (2%) | | Thyroid dysfunction | 5 (12%) | 0 | | Gastrointestinal | 3 (7%) | 0 | | Hypophysitis | 2 (5%) | 2 (5%) | | Hepatitis | 2 (5%) | 2 (5%) | | Pneumonitis | 2 (5%) | 0 | | Uveitis | 1 (2%) | 0 | | Parotitis | 1 (2%) | 0 |
|
|
Colitis and proctitis and diarrhoea . |
